GlassScriptPhysician profile
Riley M Hill
NPI 1508865361
$13,621.37
in general payments reported to CMS, 2019-2025
59 companies · $1,733 in 2025
The $1,733 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,020 · 2020: $954 · 2021: $2,075 · 2022: $2,295 · 2023: $2,468 · 2024: $2,077 · 2025: $1,733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,235 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,235.23 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,759.93 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,381.05 | 2021-2025 | |
| Lilly USA, LLC | $1,276.03 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $1,023.55 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $855.63 | 2019-2025 | Jardiance, Tradjenta |
| Janssen Pharmaceuticals, INC | $648.95 | 2019-2025 | Spravato, Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $531.52 | 2019-2024 | Trintellix |
| Abbott Laboratories | $425.15 | 2019-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $413.59 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $400.54 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Lundbeck LLC | $393.17 | 2021-2025 | Rexulti |
| Novo Nordisk INC | $363.36 | 2019-2025 | Ozempic, Rybelsus |
| Kowa Pharmaceuticals America, INC. | $357.94 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Amgen INC. | $336.29 | 2019-2025 | Evenity, Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $267.17 | 2019-2023 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Riley Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.